Supplementary Table 4C from GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
dataset
posted on 2023-04-03, 14:05 authored by David J. Duffy, Aleksandar Krstic, Thomas Schwarzl, Desmond G. Higgins, Walter KolchXLSX - 736K, Table S4C. Differentially expressed genes between Control Vs. BIO treated cells.
History
ARTICLE ABSTRACT
Neuroblastoma is an embryonal tumor accounting for approximately 15% of childhood cancer deaths. There exists a clinical need to identify novel therapeutic targets, particularly for treatment-resistant forms of neuroblastoma. Therefore, we investigated the role of the neuronal master regulator GSK3 in controlling neuroblastoma cell fate. We identified novel GSK3-mediated regulation of MYC (c-MYC and MYCN) mRNA levels, which may have implications for numerous MYC-driven cancers. In addition, we showed that certain GSK3 inhibitors induced large-scale cell death in neuroblastoma cells, primarily through activating apoptosis. mRNA-seq of GSK3 inhibitor–treated cells was performed and subsequent pathway analysis revealed that multiple signaling pathways contributed to the loss of neuroblastoma cell viability. The contribution of two of the signaling pathways highlighted by the mRNA-seq analysis was functionally validated. Inhibition of the p53 tumor suppressor partly rescued the cell death phenotype, whereas activation of canonical Wnt signaling contributed to the loss of viability, in a p53-independent manner. Two GSK3 inhibitors (BIO-acetoxime and LiCl) and one small-molecule Wnt agonist (Wnt Agonist 1) demonstrated therapeutic potential for neuroblastoma treatment. These inhibitors reduced the viability of numerous neuroblastoma cell lines, even those derived from high-risk MYCN-amplified metastatic tumors, for which effective therapeutics are currently lacking. Furthermore, although LiCl was lethal to neuroblastoma cells, it did not reduce the viability of differentiated neurons. Taken together our data suggest that these small molecules may hold potential as effective therapeutic agents for the treatment of neuroblastoma and other MYC-driven cancers. Mol Cancer Ther; 13(2); 454–67. ©2013 AACR.Usage metrics
Categories
Keywords
Cell CycleSignal transduction pathwaysCell Death And SenescenceEffectors of apoptosisComputational MethodsGene expression profilingDrug MechanismsCellular responses to anticancer drugsDrug-mediated stimulation of cell death pathwaysGene RegulationOncogenic transcription factorsGenome BiologySilencing and reactivation of gene expressionOncogenes & Tumor Suppressorsp53Pediatric CancersSmall Molecule Agents
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC